 |
|
|
| |
Are Ring Worries Affecting Use? Findings from the MTN-020/ASPIRE Phase III Dapivirine Ring Trial
|
| |
| |
Reported by Jules Levin
HIV Research for Prevention (HIVR4P), October 17-19, 2016, Chicago
Ariane van der Straten1, 2, Helen Cheng1, Elizabeth R. Brown3, KrishnaveniReddy4, Rachel Scheckter5, Mary Kate Shapley-Quinn1, Lydia Soto-Torres6, Thesla Palanee-Phillips4, Jared, Baeten7, Barbara Mensch8for the MTN-020/ASPIRE Study Team
1RTI International, Women's Global Health Imperative, San Francisco, CA, United States, 2University of California San Francisco, Department of Medicine, San Francisco, CA, United States; 3Fred Hutchinson Cancer Research Center, Statistical Center for HIV/AIDS Research and Prevention, Seattle, WA, United States, 4University of the Witwatersrand, Wits Reproductive Health and HIV Institute, Johannesburg, South Africa, 5FHI 360, Durham, NC, United States, 6NIAID/DAIDS, Bethesda, MD, USA, 7University of Washington, Department of Global Health, Seattle, WA, United States,8Population Council, New York, NY, United States
|
| |
|
|
|
|
|
